A European Medicines Agency committee on Thursday recommended EU approval of Revolution Medicines' drug ​for adults with metastatic pancreatic cancer, potentially offering patients ‌in the bloc a new option for a disease with limited effective therapies.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in